WCG acquisition expands services to patient recruitment

By Melissa Fassbender

- Last updated on GMT

ThreeWire has screened more than 2 million patients in more than 25 countries. (Image: iStock/Kritchanut)
ThreeWire has screened more than 2 million patients in more than 25 countries. (Image: iStock/Kritchanut)

Related tags Patient recruitment Clinical trial

WIRB-Copernicus Group (WCG) has acquired the global patient recruitment, enrollment, and retention firm, ThreeWire.

"The ThreeWire approach to providing global clinical trial patient recruitment, enrollment, retention, and research site optimization services is a natural fit with WCG​," Mark Summers, ThreeWire CEO told Outsourcing-Pharma.com.

According to the company, it combines technology with “on-the-ground resources” to help investigators recruit and conduct clinical studies.

Additionally, ThreeWire has more than 300 clinical research professionals, called “Enrollment Assistants,” who work at study sites to close resource gaps where needed.

Other on-site recruitment services include patient chart review as a step to identify study candidates and conducting community outreach to patient groups and referral physicians.

The company’s US headquarters are Minneapolis with another base in Frankfurt, Germany.

"Together, WCG and ThreeWire accelerate study start-up for sponsors and contract research organizations (CROs), improve ROI on clinical trials, and accelerate patient access to innovative medicines,​" said Summers.  

"With the growth that ThreeWire has experienced both domestically and globally, it was time to find an organization with which they could continue to have scalable and innovative growth while ensuring their mission and values were aligned​," he added.

As part of the acquisition, terms of which were not disclosed, ThreeWire will continue to operate as an independent organization.

"There is no plan to “fully absorb” ThreeWire into WCG. WCG’s plan for ThreeWire is to support them to operate independently, while providing resources to help the company as it continues to expand, with access to capital, complementary clinical and regulatory expertise, and corporate support​," Summers explained.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us

Products

View more

Webinars